Myelodysplastic syndrome is not merely "preleukemia".

Myelodysplastic syndrome (MDS) is a disease characterized by ineffective hematopoiesis. There are significant biologic and clinical differences between MDS and acute myeloid leukemia (AML). We studied a cohort of 802 patients, 279 (35%) with newly diagnosed MDS and 523 (65%) with newly diagnosed AML, and compared clinical and biologic characteristics of the 2 groups. Complete clinical and cytogenetic data were available on all patients, and a subgroup of patients was studied for apoptosis, angiogenesis, proliferation, and growth factors. Our results demonstrate that MDS is a discrete entity that is different from AML and is characterized primarily by increased apoptosis in early and mature hematopoietic cells. Using cell sorting and loss of heterozygosity, we demonstrate that the leukemic cells from MDS patients are capable of differentiation into mature myeloid cells and monocytes. We also demonstrate that there is a significant overlap between AML and MDS when MDS is defined on the basis of an arbitrary percentage of blasts of 20% or 30%. These data suggest that despite similarities between AML and MDS in their responses to treatment and outcomes, MDS is biologically and clinically different from AML and should not be considered an early phase of AML. The data indicate that MDS must be better defined on the basis of its biology rather than the percentage of blasts; further, the data suggest that there is a need to develop therapeutic approaches that specifically address the biologic abnormalities of MDS.

[1]  E. Estey,et al.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. , 2000, Blood.

[2]  S. Salvioli,et al.  Use of flow cytometry as a tool to study mitochondrial membrane potential in isolated, living hepatocytes. , 1998, Biochemistry. Biokhimiia.

[3]  P. Venugopal,et al.  Biologic characteristics of 164 patients with myelodysplastic syndromes. , 1999, Leukemia and Lymphoma.

[4]  H. Kantarjian,et al.  Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). , 2001, Leukemia research.

[5]  L. Koss,et al.  Cell cycle-dependent reactivity with the monoclonal antibody Ki-67 during myeloid cell differentiation. , 1988, Experimental cell research.

[6]  M. Showel,et al.  Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis , 1999, European journal of haematology.

[7]  C. Gay,et al.  Mitochondrial membrane potential changes in osteoblasts treated with parathyroid hormone and estradiol. , 1997, Experimental cell research.

[8]  J. Bennett,et al.  Modifications in the classification of primary myelodysplastic syndromes: The addition of a scoring system , 1985, Hematological oncology.

[9]  D. Gilliland,et al.  An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X. , 1994, Nucleic acids research.

[10]  The PGK-PCR clonality assay (PPCA). , 1996, Molecular biotechnology.

[11]  T. Kinoshita,et al.  Clonality analysis by methylation-specific PCR for the human androgen-receptor gene (HUMARA-MSP) , 2000, Leukemia.

[12]  Galton Da,et al.  Myelodysplastic syndromes: natural history and features of prognostic importance. , 1986, Clinics in haematology.

[13]  J. Furuyama,et al.  Clonal analysis of hematopoietic cells using a novel polymorphic site of the X chromosome , 1998, American journal of hematology.

[14]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[15]  J. Bennett,et al.  World Health Organization classification of the acute leukemias and myelodysplastic syndrome. , 2000, International journal of hematology.

[16]  Koeffler Hp.  Myelodysplastic syndromes (preleukemia). , 1986 .

[17]  S. Kain,et al.  Fluorometric and colorimetric detection of caspase activity associated with apoptosis. , 1997, Analytical biochemistry.

[18]  C. Franceschi,et al.  A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). , 1993, Biochemical and biophysical research communications.

[19]  D. Gilliland,et al.  Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. , 1996, Blood.

[20]  J. Bennett,et al.  Understanding the Myelodysplastic Syndromes. , 1997, The oncologist.

[21]  T. Manshouri,et al.  Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia. , 2001, Leukemia research.

[22]  G. Mufti,et al.  Myelodysplastic syndromes: natural history and features of prognostic importance. , 1986, Clinics in haematology.

[23]  C. Bloomfield,et al.  The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 , 2000, Modern Pathology.

[24]  E. Estey,et al.  Application of the International Scoring System for myelodysplasia to M.D. Anderson patients. , 1997, Blood.

[25]  C. Thomas,et al.  Fluorometric assessments of mitochondrial function and viability in cryopreserved bovine spermatozoa. , 1997, Biology of reproduction.

[26]  J. Craig,et al.  Flow cytometry using annexin V can detect early apoptosis in peripheral blood stem cell harvests from patients with leukaemia and lymphoma , 1998, Bone Marrow Transplantation.

[27]  A. Hagemeijer,et al.  Application of the International Prognostic Scoring System for myelodysplastic syndromes. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Cervera,et al.  Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes , 2000, British journal of haematology.

[29]  E. Estey,et al.  Highly reproducible detection and semi-quantification of telomerase activity. , 2001, BioTechniques.

[30]  J. Starý,et al.  Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes. , 2001, Leukemia research.

[31]  A. Raza,et al.  Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. , 2000, Blood.

[32]  P. Thall,et al.  Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. , 1997, Blood.

[33]  J. Diebold,et al.  THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES REPORT OF THE CLINICAL ADVISORY COMMITTEE MEETING , 2000 .

[34]  J. Bonnefoy,et al.  Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. , 1999, Cytometry.

[35]  P. Venugopal,et al.  The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows. , 1999, International journal of hematology.

[36]  H. Gisslinger,et al.  Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. , 1999, American journal of clinical pathology.

[37]  C. Westbrook,et al.  Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia , 2000, British journal of haematology.

[38]  B. Barlogie,et al.  Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. , 2000, Blood.

[39]  M. Tsurusawa,et al.  Flow cytometric determination with bromodeoxyuridine/DNA assay of sensitivity of S-phase cells to cytosine arabinoside in childhood acute lymphoblastic leukemia. , 1989, The American journal of pediatric hematology/oncology.

[40]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  H. Kantarjian,et al.  Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. , 2000, Leukemia research.

[42]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.